Evidence-biased Antidepressant Prescription

2022 ◽  
Author(s):  
Michael P. Hengartner
JAMA ◽  
2021 ◽  
Vol 326 (17) ◽  
pp. 1725
Author(s):  
Jakob Christensen ◽  
Betina B. Trabjerg ◽  
Yuelian Sun ◽  
Julie Werenberg Dreier

2006 ◽  
Vol 163 (11) ◽  
pp. 1898-1904 ◽  
Author(s):  
Robert D. Gibbons ◽  
Kwan Hur ◽  
Dulal K. Bhaumik ◽  
J. John Mann

10.1192/03-91 ◽  
2003 ◽  
Vol 183 (6) ◽  
pp. 507-513 ◽  
Author(s):  
Carolyn S. Dewa ◽  
Jeffrey S. Hoch ◽  
Elizabeth Lin ◽  
Michael Paterson ◽  
Paula Goering

BackgroundFew studies have examined the relationship between antidepressant prescription and receipt of depression-related disability benefits.AimsTo address two questions: first, is prescription of antidepressants in accordance with published clinical guides associated with better disability outcomes, and second, what is the relationship between guideline-concordant antidepressant prescription and length of disability?MethodAn observational study was conducted using administrative data from three major Canadian financial and insurance sector companies. Short-term disability and prescription drug claims records for 1996–1998 were linked for workers receiving depression-related short-term disability benefits during that time.ResultsRecommended first-line agents and recommended doses were significantly associated with return to work (χ2=6.64, P < 0.036). In addition, among those who returned to work, early intervention was significantly associated with a shortened disability episode (β=-24.1; 95% CI-34.4 to −13.8).ConclusionsDepression-related workplace disability is a problem for which there is no simple solution. These results provide an additional piece to the puzzle of helping workers disabled by depression to return to work.


2019 ◽  
Vol 61 ◽  
pp. 75-80 ◽  
Author(s):  
Nadia Fehr ◽  
Fabienne Witassek ◽  
Dragana Radovanovic ◽  
Paul Erne ◽  
Milo Puhan ◽  
...  

1999 ◽  
Vol 23 (8) ◽  
pp. 484-486 ◽  
Author(s):  
Christopher B. Kelly ◽  
Thérèse Rafferty

Aims and methodTo investigate whether changes in antidepressant prescribing have been associated with alteration in suicide rate for the period 1989–1996 in Northern Ireland. Data for antidepressant prescribing were obtained from a central unit, for Northern Ireland, using the defined daily dose system for each of the above years. The number of recorded cases of suicide and undetermined death were also obtained for this period, from Northern Ireland coroners.ResultsThere was no evidence of an association between suicide rate and antidepressant prescription (r2=0.019, F test=0.115, P=0.74), despite antidepressant use more than tripling over the study period.Clinical implicationsEven substantial increases in detection and treatment of depressive Illness may not impinge on suicide rate. It Is also possible that suicide rate may be a very poor marker of the benefits of antidepressant treatment.


1986 ◽  
Vol 20 (4) ◽  
pp. 487-491 ◽  
Author(s):  
Geoffrey D. Schrader ◽  
Andrew Gibbs ◽  
Robert G. Harcourt

A review of case notes of patients attending a general hospital psychiatric outpatient clinic revealed that 75% of patients with depressive disorders and 38% of patients with neurotic disorders were prescribed antidepressants. Antidepressants were often prescribed for long periods in low doses and in combination with benzodiazepines. There was less polypharmacy, however, with more sedating antidepressants. The results indicate that clinical prescription habits for antidepressants may still be at some variance with recommendations from the literature.


2016 ◽  
Vol 176 (11) ◽  
pp. 1608 ◽  
Author(s):  
Avash Das ◽  
Abhishek Maiti ◽  
Shirshendu Sinha

2009 ◽  
Vol 22 (1) ◽  
pp. 120-128 ◽  
Author(s):  
Christophe Arbus ◽  
Virginie Gardette ◽  
Eric Bui ◽  
Christelle Cantet ◽  
Sandrine Andrieu ◽  
...  

ABSTRACTBackground: Psychotropic medication is widely prescribed in clinical practice for the management of behavioral and psychological symptoms of dementia (BPSD) in Alzheimer's disease (AD). However, there have been few pharmaco-epidemiological studies or studies conducted in a natural setting on the real use of antidepressants in AD. The aim of this survey was to assess the prevalence of antidepressant use in AD and to identify the clinical factors associated with antidepressant prescription.Methods: REAL.FR is a four-year, prospective, multi-center study. Baseline data including demographic characteristics, clinical variables and drug intake were obtained. Depressive symptoms were determined using the Neuropsychiatric Inventory (NPI).Results: A total of 686 AD patients were included. Antidepressant treatment was prescribed for 34.8% of patients. Clinically significant depressive symptoms (NPI ≥ 4) were observed in 20.5% of the total population. Although depressed subjects were significantly more likely to be treated with antidepressants than non-depressed subjects (p<0.0001), only 60% of depressed subjects overall were prescribed an antidepressant. In multivariate analysis, clinically significant depressive symptoms were associated with antidepressant prescription although this result was only observed in subjects without a previous history of depression.Conclusions: The available data on antidepressant efficacy in BPSD other than depression (in particular, agitation, aggression and, occasionally, psychotic symptoms) do not influence prescription choices. Depressive symptoms may be taken more seriously in the absence of a previous history of depression, leading to increased antidepressant prescription rates in individuals presenting with depression for the first time.


Sign in / Sign up

Export Citation Format

Share Document